CCM
BMRN icon

Chilton Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Chilton Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-110
Closed -$10.7K – 545
2023
Q1 		$10.7K Buy
+110
New +$11.4K ﹤0.01% 454

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Chilton Capital Management's BMRN Position: Q2 2023 in Review

Chilton Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 110 shares — an estimated $10.7K sold.

Chilton Capital Management first reported a position in BMRN in Q1 2023 and held it in 1 quarter. The position peaked at $10.7K in Q1 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

  • Chilton Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Chilton Capital Management sold 110 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $10.7K.
  • Chilton Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Chilton Capital Management's BioMarin Pharmaceuticals position peaked at $10.7K in Q1 2023.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Chilton Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.